Novavax, Inc.

NASDAQ (USD): Novavax, Inc. (NVAX)

Last Price

8.70

Today's Change

+0.02 (0.23%)

Day's Change

8.37 - 8.88

Trading Volume

5,453,287

Overview

Market Cap

1 Billion

Shares Outstanding

160 Million

Avg Volume

5,708,849

Avg Price (50 Days)

9.29

Avg Price (200 Days)

10.49

PE Ratio

-3.99

EPS

-2.18

Earnings Announcement

26-Feb-2025

Previous Close

8.68

Open

8.59

Day's Range

8.37 - 8.8877

Year Range

3.53 - 23.86

Trading Volume

5,452,396

Price Change Highlight

1 Day Change

0.23%

5 Day Change

-5.13%

1 Month Change

8.21%

3 Month Change

-32.61%

6 Month Change

-37.86%

Ytd Change

72.96%

1 Year Change

76.11%

3 Year Change

-95.45%

5 Year Change

117.50%

10 Year Change

-92.68%

Max Change

-89.12%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment